Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | MMP12 | P39900 | 1/20 | 0.79 |
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MMP3 | P08254 | 1/20 | 0.64 |
| ▸ | MMP7 | P09237 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL15012437 | 0.89 | MMP1 (0.66) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL10890150 | 0.89 | MMP1 (1.00) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL6762336 | 0.87 | MMP1 (0.63) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL2760714 | 0.87 | MMP1 (0.61) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL6802713 | 0.84 | MMP1 (0.69) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL8446048 | 0.84 | MMP1 (0.69) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL8446540 | 0.84 | MMP1 (0.69) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL8446539 | 0.84 | MMP1 (0.69) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL2969958 | 0.84 | MMP1 (0.59) | MMP1GAAMMP12MMP2MMP3 | |
| SCHEMBL10788040 | 0.84 | MMP1 (0.59) | MMP1GAAMMP12MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177783-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | claimed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | claimed |
| CN-101180029-B | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD | 2011-02-16 | — | — | CN | claimed |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | claimed |
| CN-101180029-A | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD (JP) | 2008-05-14 | — | — | CN | claimed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| CN-1484633-A | N (phenylsulphonyl) glycine derivatives and their therapentic use | ʵ���Ҹ���Ү��˾ | 2004-03-24 | — | — | CN | claimed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | claimed |
| CN-1045766-C | N-aminoalkylcarbonyloxyalkylpyrrole insecticidal, acaricidal and molluscicidal agents | AMERICAN CYANAMID CO (US) | 1999-10-20 | — | — | CN | claimed |
| EP-0594942-B1 | N-aminoalkylcarbonyloxyalkylpyrrole insecticidal acaricidal and molluscicidal agents | AMERICAN CYANAMID CO (US) | 1996-09-04 | — | — | EP | claimed |
| JP-58109418-A | — | — | None | — | — | JP | disclosed |
| US-20240399776-A1 | COLOR DEVELOPER, THERMAL RECORDING MATERIAL, AND THERMAL RECORDING LAYER COATING MATERIAL | SANKO CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024034666-A1 | RUTHENIUM COMPLEX, METHOD FOR PRODUCING SAME, CATALYST COMPOSITION, OXIDATION METHOD AND METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | 国立大学法人九州大学 | 2024-02-15 | — | — | WO | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0553962-A1 | Corrosion inhibiting compositions | CIBA-GEIGY AG (CH) | 1993-08-04 | — | — | EP | disclosed |
| US-4632931-A | ANTICOAGULANTS, BRONCHODILATOR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| JP-S58109418-A | ALDOSE REDUCTASE INHIBITOR | OKUDA JUN | 1983-06-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | MMP1 755/4885GAA 1046/4885MMP12 1873/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | MMP1 3426/4885GAA 2338/4885MMP12 2760/4885 |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | MMP1 3029/4885GAA 492/4885MMP12 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.